Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
November 20 2020 - 9:10AM
Hamilton, Bermuda, November 20, 2020 – Auris
Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology, rhinology and allergy and CNS
disorders, today announced the launch of a dedicated website for
its affiliate Altamira Medica Ltd. The website,
www.altamiramedica.com, offers quick and easy access to information
about the Company’s development of AM-301, a drug-free nasal spray
intended for self-protection against risks from exposure to
airborne viruses and allergens.
Altamira Medica Ltd. was set up in September
2020 as a subsidiary of Auris Medical Holding Ltd. to focus on and
expedite the development of AM-301. Upon application into the nose,
AM-301 forms a protective gel layer on the nasal mucosa. This thin
film is designed to prevent the contact of airborne viruses and
allergens with cells; in addition, the composition serves to “trap”
such particles and help with their discharge. Together, this is
designed to reduce the risk of upper respiratory infections and
promote alleviation of allergic symptoms. The potential protective
effects of AM-301 have been demonstrated to date in a SARS-CoV-2
assay. A short contact between AM-301’s key component and the virus
suspension was sufficient to reduce the viral infectious load by up
to 99%.
“We are proud to provide further updates on our
AM-301 program through the new dedicated website“, commented Thomas
Meyer, Auris Medical’s founder, Chairman and CEO. “Since the
announcement of the program, we have received a lot of positive
feedback on our approach of providing a simple, effective and
affordable means for reducing risk when potentially exposed to
airborne viruses or allergens. We are working hard to advance the
AM-301 project quickly and aim to submit regulatory applications in
2021.”
Altamira Medica’s website will be continuously
updated with development updates, relevant background information
and press releases.
About Auris Medical
Auris Medical is a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology, rhinology and allergy and CNS
disorders. The Company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125, in Phase 2) and
for the prevention of antipsychotic-induced weight gain and
somnolence (AM-201, post Phase 1b). With AM-301, the Company is
developing a nasal spray for protection against airborne pathogens
and allergens. In addition, Auris Medical has two Phase 3 programs
under development: Sonsuvi® (AM-111) for acute inner ear hearing
loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The
Company was founded in 2003 and is headquartered in Hamilton,
Bermuda with its main operations in Basel, Switzerland. The shares
of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market
under the symbol “EARS.”
Forward-looking Statements
This press release may contain statements that
constitute “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical facts and may include statements
that address future operating, financial or business performance or
Auris Medical’s strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as “may”,
“might”, “will”, “should”, “expects”, “plans”, “anticipates”,
“believes”, “estimates”, “predicts”, “projects”, “potential”,
“outlook” or “continue”, or the negative of these terms or other
comparable terminology. Forward-looking statements are based on
management’s current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include, but are not limited to, Auris Medical’s need
for and ability to raise substantial additional funding to continue
the development of its product candidates, the ability to pursue
strategic partnering and non-dilutive funding for its Phase 3
programs, the results of Auris Medical’s review of strategic
options and the outcome of any action taken as a result of such
review, the timing and conduct of clinical trials of Auris
Medical’s product candidates, the clinical utility of Auris
Medical’s product candidates, the timing or likelihood of
regulatory filings and approvals, Auris Medical’s intellectual
property position and Auris Medical’s financial position, including
the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical’s capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption “Risk Factors” in Auris Medical’s Annual Report
on Form 20-F for the year ended December 31, 2019, and in Auris
Medical's other filings with the SEC, which are available free of
charge on the Securities Exchange Commission's website at:
www.sec.gov. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those indicated. All
forward-looking statements and all subsequent written and oral
forward-looking statements attributable to Auris Medical or to
persons acting on behalf of Auris Medical are expressly qualified
in their entirety by reference to these risks and uncertainties.
You should not place undue reliance on forward-looking statements.
Forward-looking statements speak only as of the date they are made,
and Auris Medical does not undertake any obligation to update them
in light of new information, future developments or otherwise,
except as may be required under applicable law.
Investor contact: Joseph Green Edison Advisor
for Auris Medical 646-653-7030 jgreen@edisongroup.com
or
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2023 to Sep 2024